The Rapid Development of ESBL E coli resistance to Ceftolozane-tazobactam in a Patient with a Liver Abscess. The Search for an Omnipotent Antibiotic Goes On!
Infect Disord Drug Targets. 2016 Jul 13;
Authors: Teleb M, Soto-Ruiz E, Domínguez DC, Antony S
Multi drug resistant (MDR) Pseudomonas aeruginosa and Extended-Spectrum-lactamase (ESBL) Enterobacteriaceae are becoming an increasing difficult clinical problem. Immediate resistance to some of the new antimicrobials such as ceftolozane/tazobactam is unusual and is due to a variety of mechanisms such as hy-per-production of inactivating enzymes and gene mutation. In addition, previous antimicrobial administration is a well-recognized risk factor to develop resistance. We present a patient with a liver abscess where the organism was resistant to ceftolozane/tazobactam resulting in a poor clinical outcome.
PMID: 27411471 [PubMed - as supplied by publisher]